Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting on Monday, May 6, 2019 at 15.00 at Svenska Läkaresällskapet på Klara Östra Kyrkogata 10 i Stockholm.
In order to participate in the Annual General Meeting (AGM) shareholders must be recorded in the shareholder register maintained by Euroclear Sweden AB no later than Monday April 29, 2019 and must provide notice of participation to the company no later than Monday April 29, 2019. Notification is made by mail to Infant Bacterial Therapeutics AB (publ), Bryggargatan 10, 111 21 Stockholm, via telephone at +46 70 670 1226 or by email firstname.lastname@example.org.
The notification must include the shareholder name, personal or corporate identify number, address, telephone number, registered shareholding and the names of any proxies or assistants.
In order to participate in the AGM, shareholders whose shares are registered in the name of a trustee must temporarily re-register the shares into their own name. Such registration, which may be temporary, must be completed by Monday April 29, 2019.
Shareholders represented by a proxy must submit a dated form of proxy. If the form of proxy is submitted by a legal entity, a copy of the certificate of registration or other proof of authorization for the legal entity must be attached. A formed of proxy can be downloaded from the company´s website www.ibtherapeutics.com. An original form of proxy, and where appropriate, a certificate of registration or other proof of authorization should be received by the company at the address above no later than Monday April 29, 2019.
The Nominating Committee consists, in addition to Chairman of the Board, Peter Rothschild, of Per-Erik Andersson (appointed by the company’s largest shareholder Annwall & Rothschild Investments AB), Sebastian Jahreskog (Bank Öhman S.A.) Jannis Kitsakis (Fourth AP- Fond).
The Nominating Committee proposes the following:
Attorney Erik Sjöman
Six members without deputies.
The Chairman of the Board shall receive 200,000 and an extra remuneration of SEK 400,000 for the duties as working Chairman of the Board. Other members who are not employed by the company 100 000 SEK per member. Auditing fees shall be paid in accordance with the approved invoice.
Re-election of Margareta Hagman, Lilian Henningson Wikström, Eva Idén, Anthon Jahreskog, Kristina Sjöblom Nygren and Peter Rothschild. Anders Ekblom has declined re-election.
Information about the proposed members can be found in the annual report for 2018 and on the company’s website www.ibtherapeutics.com.
Re-election of Peter Rothschild.
Re-election of Deloitte AB.
The Chairman of the Board shall convene the three largest shareholders in the company, each of which shall appoint a representative to be a member of the Nominating Committee together with the Chairman of the Board. The Nominating Committee, the ownership ratios as per June 30, 2019 will determine who are the largest shareholders in terms of voting rights. The Nominating Committee shall be chaired by the member representing the largest shareholder as determined by voting rights on this date. If any of the three largest shareholders waives their right to appoint a member of the Nominating Committee, the next shareholder shall be prepared to appoint an alternate member of the Nominating Committee in order of magnitude. The names of the three owner’s representatives shall be published as soon as they have been appointed, but no later than six months before the Annual General Meeting 2020. The Nominating Committee’s term of office extends until the new Nominating Committee is appointed.
In the event that the shareholder the Nominating Committee member represents no longer constitutes one of the three largest shareholders, the Nominating Committee, if it finds it appropriate, may dismiss that member and give a representative of the shareholder that is next in terms or voting power the opportunity to be elected. In the event that a nominated member of the Nominating Committee resigns or otherwise leaves the Nominating Committee, the shareholder who appointed the member in question shall be entitled to appoint a new representative in the Nominating Committee. If such shareholder declines to appoint a new representative, the Nominating Committee shall, if it considers it appropriate with regard to the remaining term of office, request that the shareholder that is next in terms of voting power determine, if it wishes to appoint a representative to the Nominating Committee.
The Nominating Committee shall prepare proposals in the following questions to be submitted to the Annual General Meeting 2020 for decision:
a) proposal for election of the Chairman of the AGM
b) proposal for election of Board members
c) proposal for election of the Chairman of the Board
d) proposals for determination of Board fees
e) proposal for election of the auditor
f) proposal for determination of auditor’s fees
g) proposals for a resolution regarding the Nominating Committee prior to the 2021 AGM.
The Board of Directors proposes that no dividend be paid and that the result for the period be carried forward
The Board of Directors proposes that the AGM approve the following guidelines for determining remuneration and other terms of employment for senior executives in the Group. These principles apply to employment contracts entered into after the decision of the AGM and in the event that changes are made in the existing terms after this date.
It is of fundamental importance for the Board that the principles for remuneration and other terms of employment for senior executives in the Group create long-term motivation and enable the company to retain competent employees who work to attain maximum shareholder and customer value. In order to achieve this, it is vital to uphold fair and internally balanced terms that are market-based and competitive with respect to the structure, scope and level of remuneration. The total remuneration package for the affected individuals should contain a well-balanced mix of basic salary, variable remuneration, long-term incentive schemes, pension benefits, other benefits and terms of notice/termination benefits.
Fixed salary – The fixed salary should be individual and based on the individual’s responsibility and role, as well as the individual’s competence and experience in the relevant position.
Variable remuneration – Variable remuneration shall not exceed 30 percent of the annual salary.
Long-term incentive schemes – The Board of Directors shall annually evaluate whether a long-term share-based or other share price-based incentive program should be proposed to the AGM. Other types of long-term incentive programs can be decided upon by the Board. Any compensation in the form of long-term incentive programs must be in line with generally accepted practices in the respective market.
Pensions – Senior executives who are entitled to pension shall have defined contribution pension agreements. The final pension depends on the outcome of the defined pension agreements in force.
Other benefits – Other benefits shall be of a limited value in relation to other remuneration and shall be consistent with general norms in the respective market.
Terms of notice and termination benefits – The period of notice for senior executives may not be shorter than three months.
The Board of Directors proposes that the Board be authorized to deviate from the above proposed guidelines in individual cases when there is a specific reason to do so.
The total number of shares in the company amounts to 11,226,184, consisting of 377,736 Class A shares and 10,848,448 Class B shares, carrying a total number of 14,625,808 votes.
At the AGM, if any shareholder should so request and the Board assesses that this can be done without significant damage to the company, the Board of Directors and the President shall provide information about conditions that could affect the assessment of items on the agenda and conditions that could affect the assessment of the company’s or a subsidiary’s financial situation and the company’s relationship to other group companies.
The Annual Report and other documents for the AGM will be made available at the company and on the company’s website www.ibtherapeutics.com no later than three weeks before the meeting and will be sent free of charge to all shareholders who so request and provide their postal address.
The Board of Directors of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) (“IBT”) is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing its lead drug candidate IBP-9414, to prevent NEC and improving feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics (IBT B) shares are listed on Nasdaq Stockholm.
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 70 670 1226